Oragenics raises $16.5M, advances ONP-002 Phase IIa concussion trial for Q3 2025

ORAGENICS INC

Raised $16.5M via Series H Preferred Stock and Warrants; net proceeds ~$15.2M after fees.
HREC approval secured in Australia; Southern Star Research appointed CRO; Sterling Pharma Solutions for cGMP manufacturing.
Phase IIa trial initiation anticipated Q3 2025; IND submission for Phase IIb expected Q3-Q4 2025.
Six months ended June 30, 2025: R&D expenses down 50%, G&A costs down 8%, net losses down 6% YoY.
No FDA-approved pharmacological treatment currently exists for concussion; market opportunity $8.9B by 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.